Telavancin had MIC 50 and MIC 90 values of 0.03 and 0.06 g/ml (100.0% susceptible), respectively, against methicillin-resistant and -susceptible Staphylococcus aureus. Telavancin was active against vancomycin-susceptible Enterococcus faecalis (MIC 50/90 , 0.12/0.12 g/ml; 100% susceptible) and Enterococcus faecium (MIC 50/90 , 0.03/0.06 g/ml), while higher MIC values were obtained against vancomycin-resistant E. faecium (MIC 50/90 , 1/2 g/ml) and E. faecalis (MIC 50/90 , >2/>2 g/ml). Streptococci showed telavancin modal MIC results of <0.015 g/ml, except against Streptococcus agalactiae (i.e., 0.03 g/ml). This study reestablishes the telavancin spectrum of activity against isolates recovered from the United States (2011-2012) using the revised broth microdilution method.
T
elavancin is a once-daily parenteral semisynthetic lipoglycopeptide agent approved in the United States and Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive pathogens. Telavancin was also approved in the United States and Europe for the treatment of adult patients with hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia (HABP/VABP) due to susceptible isolates of Staphylococcus aureus (methicillin-resistant S. aureus [MRSA] strains only in Europe), when alternative medicines are unsuitable (1, 2) . These indications were based on phase 3 clinical trials demonstrating noninferiority of telavancin over vancomycin (3, 4) .
Telavancin possesses bactericidal activity against clinically relevant pathogens, such as S. aureus, including MRSA, heterogeneous vancomycin-intermediate S. aureus (hVISA) and VISA isolates, and vancomycin-susceptible enterococci (5) (6) (7) (8) (9) (10) (11) . This bactericidal activity derives from a dual mechanism of action consisting of inhibition of peptidoglycan biosynthesis, similar to the glycopeptides, and interaction with the bacterial membrane to effect changes in membrane permeability and depolarization (12) .
Early in 2014, the Food and Drug Administration (FDA) approved a labeling supplement for Vibativ (telavancin) containing a revised broth microdilution method (1) that is similar to that utilized for other members of the lipoglycopeptide class (i.e., oritavancin and dalbavancin) (13, 14) . This revised method includes the use of dimethyl sulfoxide (DMSO) as the solvent for stock solution preparations and as the diluent for the dilution of stock solutions when manufacturing 96-well MIC plates. This procedure follows the current Clinical and Laboratory Standards Institute (CLSI) guidelines for water-insoluble agents (1, 15, 16) . Moreover, this revised method includes the addition of polysorbate 80 (P-80; 0.002%) to the test medium (1, 15, 16) .
This revised broth microdilution method for telavancin provides more accurate and reproducible results by minimizing drug loss during panel preparation (increased solubility) and testing (decreasing binding on plastic trays) (16) . However, this revised broth microdilution method also provides lower MIC results than those obtained by the previously established method. Consequently, quality control (QC) MIC ranges and interpretive breakpoints were reestablished (1, 15, 17) . The objective of this investigation was to reassess the activity of telavancin when tested against a contemporary collection of isolates recovered from hospitalized patients in the United States (2011-2012) using the revised MIC testing method.
A total of 10,920 consecutive, nonduplicate isolates were collected from 28 U.S. sites located in 21 states in the nine U.S. Census regions. These isolates were recovered mostly from patients with SSSI (36%), bacteremia (26%), and respiratory tract infections (24%) and were submitted to a central monitoring laboratory (JMI Laboratories, North Liberty, IA) as part of the 2011-2012 SENTRY Antimicrobial Surveillance Program. The isolates were primarily identified by the participating laboratory. Identification was confirmed by the reference monitoring laboratory (JMI Laboratories) by standard algorithms and Vitek 2 (bioMérieux, Hazelwood, MO) and/or by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, Bremen, Germany) when initial identification performed by the participating laboratory was believed to be erroneous upon receipt of the isolate.
Isolates were tested for susceptibility by broth microdilution by following the CLSI approved standard (18) . Testing was performed using panels manufactured by Thermo Fisher Scientific (Cleveland, OH). These panels provide telavancin MIC results (dilution range applied, 0.015 to 2 g/ml) equivalent to the revised FDA-approved broth microdilution method (1, 15, 16) . Bacterial inoculum density was monitored by colony counts to ensure an adequate number of cells for each testing event. Validation of the MIC values was performed by concurrent testing of CLSI-recommended QC reference strains (S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and Streptococcus pneumoniae ATCC 49619) (1, 15) . All QC results were within published acceptable ranges. The MIC interpretations for telavancin when tested against the clinical isolates were based on updated breakpoint criteria for the revised method recently approved by the FDA (1). The European Committee on Antimicrobial Susceptibility Testing (EUCAST) updated breakpoint (Յ0.12 g/ml for susceptible) for telavancin was applied against MRSA isolates. The CLSI (2014) and EUCAST (2014) breakpoint criteria were applied for comparator agents, as available (15, 19) .
Telavancin (MIC 50/90 , 0.03/0.06 g/ml) was equally potent when tested against methicillin-susceptible S. aureus (MSSA) and MRSA isolates and inhibited 100.0% of S. aureus isolates at the FDA breakpoint for susceptibility (i.e., Յ0.12 g/ml) ( Table 1) . The telavancin MIC 50 and MIC 90 results were 8-fold lower than those of daptomycin (MIC 50/90 , 0.25/0.5 g/ml), and 16-to 32-fold lower than those of linezolid (MIC 50/90 , 1/1 g/ml) and vancomycin (MIC 50/90 , 1/1 g/ml) against MRSA ( Table 2) . Other comparators, such as gentamicin, tetracycline, and trimethoprimsulfamethoxazole, were also active against MRSA (Ն92.1% susceptible). When telavancin activity was analyzed against a subset of S. aureus isolates exhibiting elevated MIC results for vancomycin (i.e., 2 to 4 g/ml), slightly higher (2-fold) modal MIC and MIC 50 values (0.06 g/ml for both, 100.0% susceptible) were obtained compared with those of the control group (i.e., vancomycin MIC, Յ1 g/ml; modal MIC and MIC 50 values of 0.03 g/ml; 100.0% susceptible) (Table 1) . Overall, a total of 66.6% of coagulase-negative staphylococci (CoNS) were methicillin resistant, and telavancin (MIC 50/90 , 0.06/0.06 g/ml) showed MIC results 16-to 32-fold lower than those of vancomycin (MIC 50/90 , 1/2 g/ ml) and 4-to 16-fold lower than those of daptomycin (MIC 50/90 , 0.25/0.5 g/ml) and linezolid (MIC 50/90 , 0.5/1 g/ml) ( Tables 1  and 2 ). Other agents tested against CoNS did not show in vitro activity, with susceptibility rates of Յ86.1% and MIC 90 values of Ͼ2 g/ml ( Table 2) .
All E. faecalis isolates were inhibited by telavancin at the FDAapproved breakpoint for susceptibility (i.e., Յ0.25 g/ml), including vancomycin-resistant isolates (VanB phenotype), except for 21 (3.2% of total) vancomycin-resistant isolates displaying a VanA phenotype (Table 1) . Telavancin (MIC 50/90 , 0.12/0.12 g/ ml) was at least 8-fold more active than the comparator agents tested against vancomycin-susceptible E. faecalis, including ampicillin (MIC 50/90 , 1/2 g/ml), vancomycin (MIC 50/90 , 1/2 g/ml), and daptomycin (MIC 50/90 , 1/2 g/ml) ( Table 2 ). While telavancin was active against vancomycin-susceptible E. faecium (MIC 50/90 , 0.03/0.06 g/ml), higher MIC values were obtained against VanA phenotype strains (MIC 50/90 , 1/2 g/ml) ( Tables 1  and 2 ). Telavancin (MIC 50/90 , 1/2 g/ml), daptomycin (MIC 50/90 , 2/2 g/ml; 99.6% susceptible), and linezolid (MIC 50/90 , 1/1 g/ ml; 99.6 to 100.0% susceptible) had in-range MIC 50 and MIC 90 results against the latter group ( Table 2 ). The tested streptococcal isolates showed low MIC results for telavancin, with MIC 50 results of Յ0.015 g/ml, except for Streptococcus agalactiae, which exhibited MIC 50 and MIC 90 results of 0.03 and 0.06 g/ml, respectively (Table 1 ). In addition, telavancin showed MIC 50 and MIC 90 values lower than those of comparator agents when tested against S. pneumoniae and viridans group streptococci, with telavancin and penicillin demonstrating the lowest and similar MIC results against beta-hemolytic streptococci ( Table 2) . The results presented here were obtained using the recent FDA-approved revised broth microdilution method (16) , which ensures a proper assessment of the telavancin MIC determination, especially when tested against staphylococci and enterococci. The MIC values described herein are lower than those obtained by the previously established broth microdilution method (20, 21) . However, the telavancin antimicrobial susceptibility rates remain high (100.0% susceptible) and very similar to those observed in earlier investigations (20, 21) . Although the revised method results in potent and lower MIC values for staphylococci, streptococci, and vancomycin-susceptible enterococci than the previous method, telavancin was less active against VanA phenotype vancomycin-resistant enterococcus, regardless of the method used (22, 23) . Moreover, these in vitro MIC results are now comparable to those reported for other lipoglycopeptide agents (i.e., oritavancin and dalbavancin) that utilize similar susceptibility testing methodologies to telavancin (24, 25) and are mostly lower than those for other comparators. Finally, this study reestablishes the in vitro potencies and susceptibility profiles of telavancin (using updated interpretive criteria) against isolates recovered from the United States (2011) (2012) .
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